{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:18:13Z","timestamp":1707524293344},"reference-count":10,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,9,20]]},"DOI":"10.7759\/cureus.18134","type":"journal-article","created":{"date-parts":[[2021,9,20]],"date-time":"2021-09-20T20:52:00Z","timestamp":1632171120000},"source":"Crossref","is-referenced-by-count":0,"title":["Epstein-Barr Virus-Negative Diffuse Large B-Cell Post-transplant Lymphoma in an Epstein-Barr Virus-Positive Recipient"],"prefix":"10.7759","author":[{"given":"Charlotte","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helena","family":"Vincentelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jenni","family":"Visuri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon","family":"Knight","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rutger","family":"Ploeg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-019-0548-7","article-title":"Epstein-Barr virus-related post-transplant lymphoproliferative disease (EBV-PTLD) in the setting of allogeneic stem cell transplantation: a comprehensive review from pathogenesis to forthcoming treatment modalities","volume":"55","author":"Al Hamed R","year":"2020","unstructured":"Al Hamed R, Bazarbachi AH, Mohty M. Epstein-Barr virus-related post-transplant lymphoproliferative disease (EBV-PTLD) in the setting of allogeneic stem cell transplantation: a comprehensive review from pathogenesis to forthcoming treatment modalities. Bone Marrow Transplant. 2020, 55:25-39. 10.1038\/s41409-019-0548-7","journal-title":"Bone Marrow Transplant"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.12990","article-title":"Donor or recipient origin of posttransplant lymphoproliferative disorders following solid organ transplantation","volume":"14","author":"Kinch A","year":"2014","unstructured":"Kinch A, Cavelier L, Bengtsson M, et al.. Donor or recipient origin of posttransplant lymphoproliferative disorders following solid organ transplantation. Am J Transplant. 2014, 14:2838-2845. 10.1111\/ajt.12990","journal-title":"Am J Transplant"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s12288-019-01182-x","article-title":"Post transplant lymphoproliferative disorder","volume":"36","author":"Gupta D","year":"2020","unstructured":"Gupta D, Mendonca S, Chakraborty S, Chatterjee T. Post transplant lymphoproliferative disorder. Indian J Hematol Blood Transfus. 2020, 36:229-237. 10.1007\/s12288-019-01182-x","journal-title":"Indian J Hematol Blood Transfus"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-013-0162-5","article-title":"Post-transplant lymphoproliferative disease (PTLD): risk factors, diagnosis, and current treatment strategies","volume":"8","author":"Al-Mansour Z","year":"2013","unstructured":"Al-Mansour Z, Nelson BP, Evens AM. Post-transplant lymphoproliferative disease (PTLD): risk factors, diagnosis, and current treatment strategies. Curr Hematol Malig Rep. 2013, 8:173-183. 10.1007\/s11899-013-0162-5","journal-title":"Curr Hematol Malig Rep"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2016.130","article-title":"EBV-negative monomorphic B-cell post-transplant lymphoproliferative disorders are pathologically distinct from EBV-positive cases and frequently contain TP53 mutations","volume":"29","author":"Courville EL","year":"2016","unstructured":"Courville EL, Yohe S, Chou D, et al.. EBV-negative monomorphic B-cell post-transplant lymphoproliferative disorders are pathologically distinct from EBV-positive cases and frequently contain TP53 mutations. Mod Pathol. 2016, 29:1200-1211. 10.1038\/modpathol.2016.130","journal-title":"Mod Pathol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfq231","article-title":"Post-transplant lymphoproliferative disorder in view of the new WHO classification: a more rational approach to a protean disease?","volume":"25","author":"Mucha K","year":"2010","unstructured":"Mucha K, Foroncewicz B, Ziarkiewicz-Wr\u00f3blewska B, Krawczyk M, Lerut J, Paczek L. Post-transplant lymphoproliferative disorder in view of the new WHO classification: a more rational approach to a protean disease?. Nephrol Dial Transplant. 2010, 25:2089-2098. 10.1093\/ndt\/gfq231","journal-title":"Nephrol Dial Transplant"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.16547","article-title":"Distinct immunopathological mechanisms of EBV-positive and EBV-negative posttransplant lymphoproliferative disorders","volume":"21","author":"Nakid-Cordero C","year":"2021","unstructured":"Nakid-Cordero C, Choquet S, Gauthier N, et al.. Distinct immunopathological mechanisms of EBV-positive and EBV-negative posttransplant lymphoproliferative disorders. Am J Transplant. 2021, 21:2846-2863. 10.1111\/ajt.16547","journal-title":"Am J Transplant"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/tri.12850","article-title":"Differential risks for adverse outcomes 3 years after kidney transplantation based on initial immunosuppression regimen: a national study","volume":"29","author":"Dharnidharka VR","year":"2016","unstructured":"Dharnidharka VR, Schnitzler MA, Chen J, et al.. Differential risks for adverse outcomes 3 years after kidney transplantation based on initial immunosuppression regimen: a national study. Transpl Int. 2016, 29:1226-1236. 10.1111\/tri.12850","journal-title":"Transpl Int"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-199512000-00007","article-title":"Mode of action of tacrolimus (FK506): molecular and cellular mechanisms","volume":"17","author":"Thomson AW","year":"1995","unstructured":"Thomson AW, Bonham CA, Zeevi A. Mode of action of tacrolimus (FK506): molecular and cellular mechanisms. Ther Drug Monit. 1995, 17:584-591. 10.1097\/00007691-199512000-00007","journal-title":"Ther Drug Monit"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000013046","article-title":"Prognostic impact of germinal center B-cell-like and non-germinal center B-cell-like subtypes of bone marrow involvement in patients with diffuse large B-cell lymphoma treated with R-CHOP","volume":"97","author":"Cho MC","year":"2018","unstructured":"Cho MC, Chung Y, Jang S, et al.. Prognostic impact of germinal center B-cell-like and non-germinal center B-cell-like subtypes of bone marrow involvement in patients with diffuse large B-cell lymphoma treated with R-CHOP. Medicine (Baltimore). 2018, 97:e13046. 10.1097\/MD.0000000000013046","journal-title":"Medicine (Baltimore)"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/71663-epstein-barr-virus-negative-diffuse-large-b-cell-post-transplant-lymphoma-in-an-epstein-barr-virus-positive-recipient","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:30:20Z","timestamp":1707507020000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/71663-epstein-barr-virus-negative-diffuse-large-b-cell-post-transplant-lymphoma-in-an-epstein-barr-virus-positive-recipient"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,20]]},"references-count":10,"URL":"https:\/\/doi.org\/10.7759\/cureus.18134","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9,20]]}}}